Atai Life Sciences N.V. (ATAI)
 NASDAQ: ATAI · Real-Time Price · USD
 5.78
 -0.08 (-1.37%)
  At close: Oct 30, 2025, 4:00 PM EDT
5.89
 +0.11 (1.90%)
  After-hours: Oct 30, 2025, 7:58 PM EDT
Atai Life Sciences Revenue
Atai Life Sciences had revenue of $719.00K in the quarter ending June 30, 2025, with 163.37% growth. This brings the company's revenue in the last twelve months to $2.31M, up 510.85% year-over-year. In the year 2024, Atai Life Sciences had annual revenue of $308.00K, down -1.91%.
Revenue (ttm) 
 $2.31M
Revenue Growth 
 +510.85%
P/S Ratio 
 536.08
Revenue / Employee 
 $42,759
Employees 
 54
Market Cap 
1.24B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 308.00K | -6.00K | -1.91% | 
| Dec 31, 2023 | 314.00K | 81.00K | 34.76% | 
| Dec 31, 2022 | 233.00K | -20.14M | -98.86% | 
| Dec 31, 2021 | 20.38M | - | - | 
| Dec 31, 2020 | - | - | - | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 63.62B | 
| AbbVie | 58.33B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Eli Lilly and Company | 53.26B | 
| Novo Nordisk | 49.11B | 
ATAI News
- 10 days ago - atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares - GlobeNewsWire
- 10 days ago - Atai Life Sciences And Beckley Psytech: Promising Emerging Leader In Psychedelics - Seeking Alpha
- 13 days ago - atai Life Sciences Announces Pricing of Public Offering of Common Shares - GlobeNewsWire
- 14 days ago - atai Life Sciences Announces Proposed Public Offering of Common Shares - GlobeNewsWire
- 14 days ago - atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression - GlobeNewsWire
- 17 days ago - Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upside - Benzinga
- 4 weeks ago - Atai Life Sciences: Still A Decent Prospect - But Only Just - Seeking Alpha
- 5 weeks ago - Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients - Benzinga